Pyxis Oncology appoints Santhosh Palani, Ph.D., CFA to board; grant of 69,760 options

Pyxis Oncology, Inc.

Santhosh Palani appointed to Pyxis Oncology board effective March 12, 2024.
Dr. Palani brings strategic and investment experience from PFM Health Sciences, NEA, and Cowen.
Received stock options for 69,760 shares at $5.70 exercise price, vesting over 3 years.
No committee assignments yet; independent director under Nasdaq standards.
Press release issued March 13, 2024 announcing the appointment.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Santhosh Palani, Ph.D., CFA

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2024-03-12
Filed: March 13, 2024, 7:59 PM ET

On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Santhosh Palani, Ph.D., CFA was appointed as Director at Pyxis Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-030817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.